Core
Technologies
Precision medicine technologies are crucial for enabling personalized treatment plans tailored to each patient’s unique characteristics.
Precision Medicine Technologies
CBmed’s in-house precision medicine laboratories encompass all wet lab objectives in immunology, including flow cytometry (FACS), tissue-based imaging (both single- and multi-plex fluorescent immunohistochemistry), advanced 2D and 3D cell culture, ex-vivo compound screening, and live cell imaging. Our commitment to high-quality standards ensures consistent reproducibility, with all technologies integrated into our laboratory information and management system.
Additionally, our wet labs collaborate closely with the CBmed data science group, which brings expertise in biostatistics, computational biology, data engineering, machine learning, and DevOps. This multidisciplinary approach aims to develop advanced data analysis workflows.
Learn More
Focus on immune phenotyping technologies
Single- and multiplex immunofluorescent staining as well as flow cytometry are commonly used in immunophenotyping to characterize the immune profile of cells, analyze cell populations, and study protein expression and localization.
Immunofluorescence refers to techniques using antibodies conjugated to fluorescent dyes to detect specific antigens in cells or tissue samples.
Flow Cytometry involves labeling cells with fluorescent antibodies and passing them through a laser beam to measure and analyze the expression of specific antigens on the cell surface or within cells.
Both methods can be used with single antibodies (single staining, singe-parameter analysis) or with multiple antibodies simultaneously (multiplex staining, multi-parameter analysis.
Contact us
| Service Category | Service Description | Typical Application | Maturity level | Example Targets (generic, not exclusive) |
|---|---|---|---|---|
| Chromogenic IHC (singleplex) | Clinically established and internally validated single-marker IHC assays for tissue-based biomarker assessment | Patient stratification, translational endpoints | L4 | CD3, CD8, PD-L1, Ki67 |
| Fluorescent IHC (singleplex) | Clinically established fluorescence-based IHC assays for enhanced sensitivity | Low-abundance marker detection | L4 | FOXP3, PD-1, Granzyme B |
| Multiplex Chromogenic IHC | Validated multiplex chromogenic IHC workflows (up to 3 markers per slide) | Spatial immune contexture | L4 | CD3 / CD8 / PD-L1 |
| Multiplex Fluorescent IHC | Validated multiplex fluorescence IHC workflows (up to 6 markers per slide) | Immune-oncology profiling | L4 | CD3 / CD8 / FOXP3 / PD-1 / PD-L1 / CD25 |
| ELISA (singleplex) | Clinically aligned, internally validated assays for biomarker quantification in human biofluids | Serum/plasma biomarkers | L4 | IL-6, CRP, TNFα |
| ECLIA (singleplex) | High-sensitivity, clinically aligned assays for quantitative biomarker analysis | Low-level biomarker detection | L4 | IFN-γ, IL-10 |
| ECLIA (multiplex) | Multiplexed biomarker quantification using validated electrochemiluminescence assays | Extensive cytokine panels, immunoprofiling | L4 | IL-2, IL-4, IL-6, IL-10, TNFα |
| Bulk RNA Sequencing | Whole-transcriptome sequencing from blood or FFPE tissue (performed with certified partner) | Gene expression profiling | L4 | MAPK signalling, PI3K/AKT pathway |
| Targeted NGS Panels | Clinically oriented targeted sequencing workflows for tissue and liquid biopsy samples (performed with certified partner) | Genomic profiling, ctDNA analysis | L4 | TP53, KRAS, EGFR, BRAF |
| RNA Scope / BaseScope | Targeted RNA detection assays for spatially resolved expression analysis | Validation of gene expression at tissue level | L3 | CD274, ERBB2, EGFR |
| Preclinical / Translational ELISA | Fit-for-purpose soluble biomarker quantification in human, cell culture or animal samples | Exploratory biomarker analysis, PD readouts | L3 | IL-6, MCP-1, VEGF |
| Multiparametric Flow Cytometry | High-dimensional immune cell profiling (>20 parameters per sample) | Immune profiling, MoA studies | L3 | CD45, CD3, CD4, CD8, CD25, CD69, FoxP3, CD25, TIGIT |
| High resolution spatial transcriptomics | Pre-analytical tissue preparation and spatial RNA profiling workflows (e.g. Xenium platform, performed with certified partner) | Spatial biology, tissue architecture analysis | L2 – L3 | Immune gene signatures, cell to cell interactions, pathways, inflammatory signalling |
| Metabolomics | Global or targeted metabolite profiling (performed with certified partner) | Pathway analysis, biomarker discovery | L1 – L2 | Lactate, amino acids, glucose metabolites |
| Tissue Microarrays (TMA) | Design, construction and staining of TMAs for medium – high throughput biomarker analysis (performed with certified partner) | Biomarker screening, cohort comparisons | L1 – L2 | PDL1, HER 2 exprexsion in multiple tumor indications |
Technologies
By integrating our advanced technologies with robust quality systems and a commitment to reproducibility, we drive the advancement of precision medicine through innovative technology development, research, and comprehensive data analysis.
Frequently Asked Questions
What are Core Technologies at CBmed?
CBmed’s Core Technologies comprise a suite of advanced laboratory and analytical methods enabling high quality precision medicine research. These include flow cytometry, immunohistochemistry, immunofluorescence, 2D/3D cell culture, live cell imaging, standard molecular and cellular assays, and compound screening. Together, they provide the experimental foundation for deep biological insight and patient tailored research.
How do Core Technologies support biomarker discovery?
By combining multi platform data – including immunophenotyping, metabolomics, imaging, and molecular analysis – with rigorous quality standards, CBmed’s Core Technologies generate comprehensive biological profiles. These datasets help researchers identify, validate, and prioritize biomarkers that are relevant for disease staging, prognosis, and therapeutic decision making.
What role does immunofluorescence play in Core Technologies?
Immunofluorescence enables the visualization of specific proteins or cellular structures using fluorescently labeled antibodies. This technique provides high resolution spatial information, supporting detailed immune profiling and mechanistic studies that help clarify disease pathways.
How is the LSRFortessa flow cytometer used within CBmed’s Core Technologies?
The LSRFortessa enables rapid, multiparametric analysis of individual cells. By measuring fluorescence signals from labeled antibodies as cells pass through laser detectors, it allows precise quantification and characterization of cell populations, immune subsets, and signaling states.
Why do Core Technologies include advanced 2D and 3D cell culture models?
2D monolayer cultures and 3D spheroid models recreate biological conditions at different levels of complexity. Especially 3D cultures more closely mimic human tissue architecture and tumor microenvironments, enabling more predictive studies of cell behavior, drug responses, and disease mechanisms.
How do Core Technologies integrate with data science at CBmed?
Core Technologies produce rich, high dimensional datasets that feed directly into CBmed’s data science pipelines. Using biostatistics, computational biology, and machine learning, these datasets are transformed into actionable insights – supporting biomarker discovery, treatment stratification, and precision medicine innovation.